837 related articles for article (PubMed ID: 16600985)
1. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
[TBL] [Abstract][Full Text] [Related]
2. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
3. CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies.
Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Trenkwalder C; Brechlin P; Rüther E; Kornhuber J; Otto M; Wiltfang J
J Neural Transm (Vienna); 2006 Nov; 113(11):1771-8. PubMed ID: 16906356
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders.
Nutu M; Zetterberg H; Londos E; Minthon L; Nägga K; Blennow K; Hansson O; Ohrfelt A
Dement Geriatr Cogn Disord; 2013; 36(1-2):99-110. PubMed ID: 23860354
[TBL] [Abstract][Full Text] [Related]
5. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
[TBL] [Abstract][Full Text] [Related]
6. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
[TBL] [Abstract][Full Text] [Related]
7. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
8. Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.
Wiltfang J; Esselmann H; Bibl M; Smirnov A; Otto M; Paul S; Schmidt B; Klafki HW; Maler M; Dyrks T; Bienert M; Beyermann M; Rüther E; Kornhuber J
J Neurochem; 2002 May; 81(3):481-96. PubMed ID: 12065657
[TBL] [Abstract][Full Text] [Related]
9. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson's disease dementia.
Gmitterová K; Gawinecka J; Llorens F; Varges D; Valkovič P; Zerr I
Eur Arch Psychiatry Clin Neurosci; 2020 Jun; 270(4):461-470. PubMed ID: 30083957
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
[TBL] [Abstract][Full Text] [Related]
12. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease.
Bougea A; Stefanis L; Paraskevas GP; Emmanouilidou E; Efthymiopoulou E; Vekrelis K; Kapaki E
J Neurol; 2018 Oct; 265(10):2295-2301. PubMed ID: 30083953
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
[TBL] [Abstract][Full Text] [Related]
14. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
[TBL] [Abstract][Full Text] [Related]
15. CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD.
Stefani A; Brusa L; Olivola E; Pierantozzi M; Martorana A
J Neural Transm (Vienna); 2012 Jul; 119(7):861-75. PubMed ID: 22622365
[TBL] [Abstract][Full Text] [Related]
16. Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia.
Bibl M; Esselmann H; Lewczuk P; Trenkwalder C; Otto M; Kornhuber J; Wiltfang J; Mollenhauer B
Int J Alzheimers Dis; 2010 Aug; 2010():. PubMed ID: 20862375
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
[TBL] [Abstract][Full Text] [Related]
18. Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
Jellinger KA; Korczyn AD
BMC Med; 2018 Mar; 16(1):34. PubMed ID: 29510692
[TBL] [Abstract][Full Text] [Related]
19. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides.
Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J
Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]